Literature DB >> 12412827

Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.

Michael D Perloff1, Lisa L von Moltke, David J Greenblatt.   

Abstract

This study investigated fexofenadine (FXD) transport and the inhibition of FXD transport in Caco-2 cell monolayer transwells, using rhodamine 123 (RH123) transport as a positive control. FXD transport from the basolateral (B) to apical (A) compartment was fivefold higher than A to B transport. FXD transport was linear with respect to time (up to 270 min) and concentration (up to 300 microm). Similar results were seen with the positive control RH123. Ritonavir (100 PM) and verapamil (100 microm) reduced transport of FXD and RH123 by more than 80%, whereas transport was not inhibited by 100 m indomethacin or 2 mM probenecid. This suggests predominantly P-glycoprotein (P-gp)-mediated transport as opposed to transport by multidrug resistance protein. In concentration-response experiments, FXD transport was inhibited by verapamil and ritonavir with IC50 values of 6.5 microm and 5.4 microm, respectively. Results from this in vitro study demonstrate differential transport of FXD across Caco-2 cell monolayers and inhibition of FXD transport by established P-gp inhibitors. Thefindings support the use of FXD as an index or probe compound to reflect P-gp activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412827     DOI: 10.1177/009127002762491370

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  18 in total

Review 1.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

Review 2.  Fruit juice inhibition of uptake transport: a new type of food-drug interaction.

Authors:  David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Authors:  Mikiko Shimizu; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

4.  The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.

Authors:  Satish Kumar Bedada; Praveen Kumar Boga
Journal:  Eur J Clin Pharmacol       Date:  2016-12-15       Impact factor: 2.953

5.  Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.

Authors:  Christine Y Malati; Sarah M Robertson; Jennifer D Hunt; Cheryl Chairez; Raul M Alfaro; Joseph A Kovacs; Scott R Penzak
Journal:  J Clin Pharmacol       Date:  2011-06-06       Impact factor: 3.126

6.  Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers.

Authors:  G Peytavin; C Gautran; C Otoul; A C Cremieux; B Moulaert; F Delatour; M Melac; M Strolin-Benedetti; R Farinotti
Journal:  Eur J Clin Pharmacol       Date:  2005-05-12       Impact factor: 2.953

7.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Authors:  E D Kharasch; P S Bedynek; A Walker; D Whittington; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

8.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

9.  The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.

Authors:  Tomonori Tateishi; Masatomo Miura; Toshio Suzuki; Tsukasa Uno
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

10.  A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect".

Authors:  Christina S Won; Tian Lan; Karen M Vandermolen; Paul A Dawson; Nicholas H Oberlies; Wilbur W Widmer; Yolanda V Scarlett; Mary F Paine
Journal:  J Clin Pharmacol       Date:  2013-07-23       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.